FDA Grants Traditional Approval for Selpercatinib for Medullary Thyroid Cancer with a RET Mutation By Ogkologos - November 6, 2024 650 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LIBRETTO-531 study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR How erectile dysfunction drugs could be the key to overcoming treatment... June 21, 2022 4,000 Cancer Patients Affected by Diluted Chemotherapy Doses from Crooked Pharmacist September 17, 2020 Gentle regular exercise could reduce the risk of liver cancer in... February 15, 2021 Radio Hosts Test Sanity For Charity By Listening to ‘Baby Shark’... November 20, 2019 Load more HOT NEWS Women Diagnosed with Early Breast Cancer Since 2000 Have About a... Appendix Cancers Are Genetically Distinct from Other Gastrointestinal Cancers, Study Shows Our nurses answer your frequently asked questions about cancer FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Mantle Cell Lymphoma
